Sano Genetics streamlines clinical trials thanks to $11.4 funding

Sano Genetics, a Cambridge-based company, has successfully raised $11.4m in a new funding round. This funding will support the company’s mission to revolutionize precision medicine through the use of artificial intelligence in clinical trials. The platform aims to simplify and accelerate the process of bringing new drugs to market by leveraging AI technology for trial management. With a total of $22m raised, the company has experienced significant growth and demand for its product. Sano Genetics has combined genetic testing, recruitment, and long-term engagement into a single platform, making it easier and faster for precision medicine teams to enroll participants. The platform has already shown promising results, with claims of onboarding participants up to three times faster than traditional methods. This new funding will allow the company to integrate additional AI tools and continue its growth trajectory.